Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q03431

UPID:
PTH1R_HUMAN

ALTERNATIVE NAMES:
PTH/PTHrP type I receptor; Parathyroid hormone 1 receptor

ALTERNATIVE UPACC:
Q03431; Q2M1U3

BACKGROUND:
The Parathyroid hormone 1 receptor is integral to regulating mineral ion homeostasis and skeletal development, mediated by its interaction with parathyroid hormone and related peptides. Its signaling mechanisms are vital for bone growth and calcium metabolism.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Parathyroid hormone 1 receptor could open doors to potential therapeutic strategies for rare skeletal disorders such as Metaphyseal chondrodysplasia, Jansen type, and others. Developing receptor modulators may offer new avenues for treating these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.